Preclinical Research Results of Doer Biologics' DR10627 Published in Diabetes, Metabolic Syndrome and Obesity

2024.04.16

On April 5, 2024, the preclinical research results of DR10627, a novel GLP-1R/GIPR dual agonist co-developed by Zhejiang Doer Biologics Co., Ltd. (Doer Biologics) and Zhejiang Heze Pharmaceutical Technology Co., Ltd（Heze Pharmaceutical）, were published in Diabetes, Metabolic Syndrome and Obesity (JCR Impact Factor: 3.3 in 2022, 5-year average of 3.6). The article is titled "DR10627, a Novel Dual Glucagon‑like Peptide‑1 and Gastric Inhibitory Polypeptide Receptor Agonist for the Treatment of Obesity and Type 2 Diabetes Mellitus". Dr. Yanshan Huang, founder/CEO of Doer Biologics, is the corresponding author of this paper.

Type 2 diabetes and obesity are metabolic diseases that threaten human health and life. Type 2 diabetes is often accompanied by obesity. While current incretin mimetics like glucagon-like peptide-1 (GLP-1) exhibit significant hypoglycemic effects, their weight-loss efficacy is suboptimal and they are associated with side effects such as nausea and vomiting. Dual agonists targeting both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors can exert synergistic effects in regulating blood glucose and reducing body weight, while also improving lipid homeostasis and mitigating adverse reactions like nausea and vomiting. This makes them highly promising candidates for the treatment of type 2 diabetes and obesity.

DR10627, a GLP-1R/GIPR dual agonist, is a chemically synthesized small peptide consisting of 39 amino acids. Based on the GLP-1 sequence, it incorporates mutation sites associated with GIP activity and is further conjugated with a long-chain fatty acid to extend its plasma half-life. Preclinical study results demonstrate that DR10627 exhibits potent GLP-1R and GIPR agonistic activity in vitro, favorable pharmacokinetic properties in cynomolgus monkeys, and effectively lowers blood glucose levels in db/db mice while improving body weight and lipid metabolism in diet-induced obese (DIO) rats. DR10627 has currently progressed to Phase I clinical trials (For details, refer to Doer Biologics WeChat official account article "Doer Biologics' DR10627 Receives IND Clinical Approval" published on January 30, 2022).

Full text access link: https://doi.org/10.2147/dmso.s457830